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Analytical performance of the homogeneous enzyme immunoassay (EIA) for the determination of serum gentamicin has been reported recently by several investigators (2, 3, 5) . During our evaluation of EIA and correlation with a standard microbiological assay, we noted two facets which can significantly affect precision and accuracy of the assay. We report here the apparent lack of specimen stability upon freezing and the nonuniformity of variance observed for the EIA.
Serum samples were collected from patients hospitalized at the Veterans Administration Medical Center, Seattle, Wash., who were receiving gentamicin. For The EIA was performed with reagents obtained from Syva Co., Palo Alto, Calif. Sample and reagents were diluted and mixed with a pipetter dilutor (model 1500, Cavro Scientific Instruments, Sunnyvale, Calif.) in accordance with Syva's instructions (Emit-amd Gentamicin Assay; Syva Co.). The mixture was aspirated into a spectrophotometer (Gilford Stasar III, Gilford Instrument Laboratories, Inc., Oberlin, Ohio) equipped with a flow cell thermostatically maintained at 30°C (model 3017T thermal control unit; Gilford Instrument Laboratories). A two-point fixed-time kinetic measurement was made at 340 nm. Absorbance readings were taken at 15 and 45 s after aspiration of the sample, and the difference (A A) was printed out by a timer-printer (CP-5000 EMIT Clinical Processor; Syva Co.). The timer-printer also corrected A A values for the zero calibrator absorbance difference (A AO), performed a fiveparameter logit transformation on the stored calibrator data, and printed out computed gentamicin concentrations for specimens. Acceptance criteria for standard curve, control sample, and results of duplicate patient assays were those recommended by Syva. The lyophilized serumbased calibrators supplied by Syva were reconstituted in accordance with the manufacturer's instructions and used to standardize the EIA method at gentamicin concentrations of 0.0, 1.0, 2.0, 4.0, 8.0, and 16.0 ,ug/ml.
A standard large-plate disk-diffusion technique described by Lund et al. (1) was used for the microbiological assay. The method employed antibiotic medium no. 1 (Oxoid Ltd., London) which was adjusted to pH 7.8 and seeded with Klebsiella pneumoniae (ATCC 27799). Calibration standards for the microbiological assay and controls were prepared by diluting portions of a 1,000-,ug/ml stock standard with gentamicin-free pooled human serum (GIBCO Laboratories, Grand Island, N.Y.) to give samples containing 1.5, 3.0, 6.0, 10.0, and 12.0 ,ug of gentamicin per ml. These samples were stored in plastic at -60°C until use. The stock standard was prepared from high-potency gentamicin sulfate powder (Schering Corp., Bloomfield, N.J.) in 0.1 M potassium phosphate buffer, pH 8.0.
Intrabatch precision was evaluated by assay of control materials containing gentamicin concentrations ranging from 1.5 to 12.0 p,g/ml a minimum of 18 times. The results are presented in Table 1 . For gentamicin concentrations of 1.5 to 10.0 ,ug/ml, the coefficient of variation (CV) obtained ranged from 3.3 to 6.5%. The CV of 17.6% noted for the 12.0-j.tg/ml sample prompted repeat assays of the sample after a 1:2 dilution with pooled human serum. This resulted in a CV of 4.2%. For gentamicin concentrations within 1.5 to 10.0 ,ug/ml, mean recoveries of 92 to 102% were obtained. The mean recovery for the undiluted 12.0-,ug/ml control was 120%. As a result of the poor intrabatch precision demonstrated at high gentamicin concentrations, the intraday precision in establishing a standard curve was tested by performing the calibration procedure four times within a 7-h period on a single day. A mean standard curve was plotted from the data, and apparent gentamicin concentrations were derived for all calibrators over the 7-h interval. The results, summarized in Table 2 , indicate a high degree of imprecision at extremes of the calibration curve. CVs obtained for the 1.0-and 16.0-p.g/ml calibrators were 23.8 and 19.4%, respectively.
The manufacturer states that the EIA technique is designed to quantitate accurately within the range 1.0 to 16.0 ,ug/ml with optimum precision, defined as a CV of less than 10%, achievable in the range of 2 to 10 ,ug of gentamicin per ml (EMIT-amd Gentamicin Assay; Syva Co. (4) . However, none of the previous reports have addressed the problem associated with the five-parameter logit fit of the absorbance versus concentration data for the EIA gentamicin procedure.
Correlation of the EIA technique with the microbiological assay was studied by assay of a total of 90 patient sera with gentamicin concentrations ranging from <1.5 to 8.6 p.g/ml, as determined by microbiological assay. Table 3 illustrates the least-squares linear regression statistics obtained. Of 70 patient sera assayed on the day of specimen collection, 50 yielded gentamicin levels within the assay range of both methods. Least-squares linear regression analysis of these data gave a correlation coefficient of 0.96, a slope of 0.91, and a y-intercept of -0.20. Of 20 specimens stored at -60°C in plastic tubes before EIA analysis, 15 yielded quantitative results by both methods. Statistical analysis of the correlation data gave a correlation coefficient of 0.95, a slope of 0.69, and a y-intercept of 0.75, suggesting degradation of the samples under the sample-handling conditions employed. Results obtained for samples pretreated with 1-lactamase II were not significantly different from those obtained for nontreated samples.
The mechanism for the apparent loss of gentamicin (average 22%) upon freezing of specimens before EIA determination is not clear. O'Leary et al. reported no significant difference between results for five specimens assayed immediately after collection and again on each of 4 days of storage at 4°C and the results for five specimens assayed immediately after collection and again on three occasions subsequent to storage at -20°C for an unspecified time. In addition, these investigators reported no statistical difference between results obtained for specimens containing gentamicin in the presence of P-lactam compounds assayed immediately upon collection and results obtained for specimens assayed after storage at room temperature for 72 h (2). We are currently investigating specimen stability under various experinmental conditions, and we feel that laboratories should be alerted to possible loss of gentamicin upon freezing.
In summary, there appears to be considerable loss of precision and accuracy at the extreme ends of the calibration curve, and we strongly recommend that each laboratory using the EIA gentamicin technique establish standard curve precision and limits of assay linearity, as appropriate for clinical application at the laboratory's institution. Additionally, control samples containing gentamicin concentrations at the established linearity limits should be routinely employed to verify linearity. We further recommend that assays be run on the day of sample collection when possible, as there may be significant loss of gentamicin upon storage for extended periods. Under these conditions, we have found the precision and accuracy obtained for the EIA technique to be consistent with the findings of other investigators (2, 3, 5) and to represent a marked improvement in performance over the microbiological assay (1) . The rapid analysis afforded by the EIA technique readily permits timely reassay of a diluted specimen in instances in which the laboratory-defined limit of linearity is exceeded. The number of specimens containing gentamicin above our upper limit of 8 ,ug/ml represented about 1% of our total gentamicin work load.
